Grant: Catalyst Grant: Systems Biology Approaches to Immunotherapy

Organ transplantation remains the therapy of choice for patients with end-stage vital organ failure. Pharmaceutical and biological engineering have produced a collection of immunosuppressive agents used to prevent graft rejection. However, although these agents reduce the rate of acute rejection and some may retard chronic vascular injury, graft loss and other complications associated with life-long immunosuppression remain important barriers to success. A new approach for controlling the host response to the graft is needed, but this requires a better understanding of the cellular and molecular networks involved.